Psyence Biomedical Ltd. (PBM) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$3.44

From 52W high−81.95%

Volume12275.00

Market cap$11.94M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$3.44

From 52W high

−81.95%

Volume

12275.00

Market cap

$11.94M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.7x

P/E (TTM)

—

RSI (14)

34.5

MomentumView details →

1D Return

−4.86%

YTD Return

−33.26%

SummaryUpdated Mar 1, 2026

Psyence Biomedical Ltd. (NASDAQ:PBM) is a Canadian biotechnology company founded in 2020 and publicly traded since December 2021. The company specializes in developing botanical psilocybin-based psychedelic medicines for treating mental health conditions, particularly in palliative care settings. Based in Toronto, Canada, Psyence operates as a subsidiary of Psyence Group Inc. and represents one of the emerging players in the nascent psychedelic medicine industry, focusing on naturally-sourced psilocybin rather than synthetic alternatives.

Ask drillr about Psyence Biomedical Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.7x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−58.45%

ROA (TTM)

−54.15%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−4.86%

YTD Return

−33.26%

1Y Return

−80.63%

RSI (14)

34.5

vs 50D SMA

−33.83%

vs 200D SMA

−20.70%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

8.09x

Quick Ratio

8.09x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−26.25M

Op. CF (TTM)

—

Latest newsMore news →

Psyence Biomedical Ltd. announced a share-for-share exchange with Psyence Labs Ltd. alongside a $5 million cash investment to advance its U.S. ibogaine program.42d ago

Psyence Biomedical Ltd. announced the formation of Texas Ibogaine Research Corporation, a Texas-based U.S. vehicle to coordinate its ibogaine development activities including supply, regulatory engagement and potential clinical development.51d ago

Similar companies

CollPlant Biotechnologies Ltd.CLGN Lipocine Inc.LPCN Tvardi Therapeutics, Inc.TVRD Lisata Therapeutics, Inc.LSTA Cellectar Biosciences, Inc.CLRB Synlogic, Inc.SYBX Find similar companies →

Latest newsMore news →

Psyence Biomedical Ltd. announced a share-for-share exchange with Psyence Labs Ltd. alongside a $5 million cash investment to advance its U.S. ibogaine program.42d ago Psyence Biomedical Ltd. announced the formation of Texas Ibogaine Research Corporation, a Texas-based U.S. vehicle to coordinate its ibogaine development activities including supply, regulatory engagement and potential clinical development.51d ago Psyence Labs Ltd. disclosed a 30.1% stake in Psyence Biomedical Ltd. via a 13D/G filing.155d ago